Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples

Clin Chem Lab Med. 2011 Sep 23;50(1):61-5. doi: 10.1515/CCLM.2011.731.

Abstract

Background: A recent study reported that an 18-analyte multiplexed plasma panel of signaling proteins differentiated Alzheimer's disease (AD) from controls. This study measured mRNA expression for nine of these promising bio-markers in 23 AD patients and 23 age- and sex-matched controls.

Methods: Total RNA was isolated from PaxGene RNA tubes. Relative mRNA expression levels of CCL5 [RANTES], CSF1, ICAM1, IGFBP6, IL1A, IL3, IL8, PDGFB and TNF were determined by Q-RT-PCR, with GAPDH as housekeeping gene.

Results: A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients and controls (p interaction <0.10). Especially, the relative expression level of CCL5 was lower in AD patients than in controls (p<0.005). Across groups, levels of both CCL5 and TNF were correlated to CSF levels of τ (r=0.39, r=0.32), pτ-181 (r=0.38, r=0.33), and MMSE (r=-0.31, r=-0.33, all p<0.05).

Conclusions: The measured panel, and especially CCL5, could aid in the differentiation of AD from controls.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism
  • Chemokine CCL5 / blood*
  • Chemokine CCL5 / metabolism
  • Down-Regulation*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • RNA, Messenger / metabolism

Substances

  • Chemokine CCL5
  • RNA, Messenger